OECD GUIDELINE FOR THE TESTING OF CHEMICALS

Reconstructed human Cornea-like Epithelium (RhCE) test method for identifying chemicals not requiring classification and labelling for eye irritation or serious eye damage

INTRODUCTION

1. *Serious eye damage* refers to the production of tissue damage in the eye, or serious physical decay of vision, following application of a test chemical to the anterior surface of the eye, which is not fully reversible within 21 days of application, as defined by the United Nations Globally Harmonized System of Classification and Labelling of Chemicals (UN GHS) (1). Also according to UN GHS, *eye irritation* refers to the production of changes in the eye following the application of a test chemical to the anterior surface of the eye, which are fully reversible within 21 days of application. Test chemicals inducing serious eye damage are classified as UN GHS Category 1, while those inducing eye irritation are classified as UN GHS Category 2. Test chemicals not classified for eye irritation or serious eye damage are defined as those that do not meet the requirements for classification as UN GHS Category 1 or 2 (2A or 2B) i.e., they are referred to as UN GHS No Category.

2. The assessment of serious eye damage/eye irritation has typically involved the use of laboratory animals (OECD Test Guideline (TG) 405; adopted in 1981 and revised in 1987, 2002 and 2012) (2). In relation to animal welfare concerns, TG 405 recommends the use of a sequential testing strategy for the determination of the serious eye damage/eye irritation potential of chemicals. This testing strategy is described in a Supplement to the Guideline and includes the use of validated, scientifically valid and accepted *in vitro* test methods, thus decreasing or avoiding pain and suffering of animals (2).

3. This Test Guideline describes an *in vitro* procedure allowing the identification of chemicals (substances and mixtures) not requiring classification and labelling for eye irritation or serious eye damage in accordance with UN GHS. It makes use of reconstructed human cornea-like epithelium (RhCE) which closely mimics the histological, morphological, biochemical and physiological properties of the human corneal epithelium. Four other *in vitro* test methods have been validated, considered scientifically valid and adopted as OECD Test Guidelines (TGs) 437 (3), 438 (4), 460 (5) and 491 (6) to address the human health endpoint serious eye damage/eye irritation.

4. Two validated test methods using commercially available RhCE models are included in this Test Guideline. Formal validation studies for assessing eye irritation/serious eye damage have been conducted (7)(8)(9)(10)(11)(12)(13) using EpiOcular™ Eye Irritation Test (EIT) and the SkinEthic™ Human Corneal Epithelium (HCE) Eye Irritation Test (EIT), which make use of a commercially available RhCE tissue construct as test system, and which are referred to in the following text as the Validated Reference Methods – VRM 1 and VRM2, respectively. From these validation studies and its independent peer review (9)(12) it was concluded that the EpiOcular™ EIT and SkinEthic™ HCE EIT are able to correctly identify chemicals (both substances and mixtures) not requiring classification and labelling for eye irritation or serious eye damage according to UN GHS (1), and the test methods were recommended as scientifically valid for that purpose (13).
5. It is currently generally accepted that, in the foreseeable future, no single in vitro test method will be able to fully replace the in vivo Draize eye test (2)(14) to predict across the full range of serious eye damage/eye irritation responses for different chemical classes. However, strategic combinations of several alternative test methods within (tiered) testing strategies such as the Bottom-Up/Top-Down approach may be able to fully replace the Draize eye test (15). The Bottom-Up approach (15) is designed to be used when, based on existing information, a chemical is expected not to cause sufficient eye irritation to require a classification, while the Top-Down approach (15) is designed to be used when, based on existing information, a chemical is expected to cause serious eye damage. The EpiOcular™ EIT and SkinEthic™ HCE EIT are recommended to identify chemicals that do not require classification for eye irritation or serious eye damage according to UN GHS (UN GHS No Category) (1) without further testing, within a testing strategy such as the Bottom-Up/Top-Down approach suggested by Scott et al. e.g., as an initial step in a Bottom-Up approach or as one of the last steps in a Top-Down approach (15). However, the EpiOcular™ EIT and SkinEthic™ HCE EIT are not intended to differentiate between UN GHS Category 1 (serious eye damage) and UN GHS Category 2 (eye irritation). This differentiation will need to be addressed by another tier of a test strategy (15). A test chemical that is identified as requiring classification for eye irritation/serious eye damage with EpiOcular™ EIT or SkinEthic™ HCE EIT will thus require additional testing (in vitro and/or in vivo) to establish a definitive classification (UN GHS No Category, Category 2 or Category 1), using e.g., TG 437, 438, 460 or 491.

6. The purpose of this Test Guideline is to describe the procedure used to evaluate the eye hazard potential of a test chemical based on its ability to induce cytotoxicity in a RhCE tissue construct, as measured by the MTT assay (16) (see paragraph 22). The viability of the RhCE tissue following exposure to a test chemical is determined in comparison to tissues treated with the negative control substance (% viability), and is then used to predict the eye hazard potential of the test chemical.

7. Performance Standards (17) are available to facilitate the validation of new or modified in vitro RhCE-based test methods similar to EpiOcular™ EIT and SkinEthic™ HCE EIT, in accordance with the principles of Guidance Document No. 34 (18), and allow for timely amendment of this Test Guideline for their inclusion. Mutual Acceptance of Data (MAD) will only be guaranteed for test methods validated according to the Performance Standards, if these test methods have been reviewed and included in this Test Guideline by the OECD.

DEFINITIONS

8. Definitions are provided in Annex I.

INITIAL CONSIDERATIONS AND LIMITATIONS

9. This Test Guideline is based on commercial three-dimensional RhCE tissue constructs that are produced using either primary human epidermal keratinocytes (i.e., EpiOcular™ OCL-200) or human immortalized corneal epithelial cells (i.e., SkinEthic™ HCE/S). The EpiOcular™ OCL-200 and SkinEthic™ HCE/S RhCE tissue constructs are similar to the in vivo corneal epithelium three-dimensional structure and are produced using cells from the species of interest (19)(20). Moreover, the test methods directly cover multiple cellular effects determining the overall in vivo serious eye damage/eye irritation response of a chemical upon ocular exposure, i.e., penetration of the chemical through the cornea and production of cell and tissue damage. Cell damage can occur by several modes of action (see paragraph 21), but cytotoxicity plays an important, if not the primary, mechanistic role in determining the overall serious eye damage/eye irritation response of a chemical, manifested in vivo mainly by corneal opacity, iritis, conjunctival redness and/or conjunctival chemosis, regardless of the physicochemical processes underlying tissue damage.

10. A wide range of chemicals, covering a large variety of chemical types, chemical classes, molecular weights, LogPs, chemical structures, etc., have been tested in the validation study underlying this
Test Guideline. The EpiOcular™ EIT validation database contained 113 chemicals in total, covering 95 different organic functional groups according to an OECD QSAR toolbox analysis (8)(13). The majority of these chemicals represented mono-constituent substances, but several multi-constituent substances (including 3 homopolymers, 5 copolymers and 10 quasi polymers) were also included in the study. In terms of physical state and UN GHS Categories, the 113 tested chemicals were distributed as follows: 13 Category 1 liquids, 15 Category 1 solids, 6 Category 2A liquids, 10 Category 2A solids, 7 Category 2B liquids, 7 Category 2B solids, 27 No Category liquids and 28 No Category solids (8)(9). The SkinEthic™ HCE EIT validation database contained 200 chemicals in total, covering 165 different organic functional groups (8)(10)(11)(13). The majority of these chemicals represented mono-constituent substances, but several multi-constituent substances (including 10 polymers) were also included in the study. In terms of physical state and UN GHS Categories, the 200 tested chemicals were distributed as follows: 27 Category 1 liquids, 24 Category 1 solids, 19 Category 2A liquids, 10 Category 2A solids, 9 Category 2B liquids, 8 Category 2B solids, 50 No Category liquids and 53 No Category solids (10)(11).

11. This Test Guideline is applicable to substances and mixtures, and to solids, liquids, semi-solids and waxes. The liquids may be aqueous or non-aqueous; solids may be soluble or insoluble in water. Whenever possible, solids should be ground to a fine powder before application; no other pre-treatment of the sample is required. Gases and aerosols have not been assessed in a validation study. While it is conceivable that these can be tested using RhCE technology, the current Test Guideline does not allow testing of gases and aerosols.

12. Test chemicals absorbing light in the same range as MTT formazan (naturally or after treatment) and test chemicals able to directly reduce the vital dye MTT (to MTT formazan) may interfere with the tissue viability measurements and need the use of adapted controls for corrections. The type of adapted controls that may be required will vary depending on the type of interference produced by the test chemical and the procedure used to quantify MTT formazan (see paragraphs 37-43).

13. Results generated in pre-validation (21)(22) and full validation (8)(10)(11) studies have demonstrated that both EpiOcular™ EIT and SkinEthic™ HCE EIT are transferable to laboratories considered to be naïve in the conduct of the assays and also to be reproducible within- and between laboratories. Based on these studies, the level of reproducibility in terms of concordance of predictions that can be expected from EpiOcular™ EIT from data on 113 chemicals is in the order of 95% within laboratories and 93% between laboratories. The level of reproducibility in terms of concordance of predictions that can be expected from SkinEthic™ HCE EIT from data on 120 chemicals is in the order of 92% within laboratories and 95% between laboratories.

14. The EpiOcular™ EIT can be used to identify chemicals that do not require classification for eye irritation or serious eye damage according to the UN GHS classification system (1). Considering the data obtained in the validation study (8), the EpiOcular™ EIT has an overall accuracy of 80% (based on 112 chemicals), sensitivity of 96% (based on 57 chemicals), false negative rate of 4% (based on 57 chemicals), specificity of 63% (based on 55 chemicals) and false positive rate of 37% (based on 55 chemicals), when compared to reference in vivo rabbit eye test data (OECD TG 405) (2)(14) classified according to the UN GHS classification system (1). A study where 97 liquid agrochemical formulations were tested with EpiOcular™ EIT demonstrated a similar performance of the test method for this type of mixtures as obtained in the validation study (23). The 97 formulations were distributed as follows: 21 Category 1, 19 Category 2A, 14 Category 2B and 43 No Category, classified according to the UN GHS classification system (1) based on reference in vivo rabbit eye test data (OECD TG 405) (2)(14). An overall accuracy of 82% (based on 97 formulations), sensitivity of 91% (based on 54 formulations), false negative rate of 9% (based on 54 formulations), specificity of 72% (based on 43 formulations) and false positive rate of 28% (based on 43 formulations) were obtained (23).

15. The SkinEthic™ HCE EIT can be used to identify chemicals that do not require classification for eye irritation or serious eye damage according to the UN GHS classification system (1). Considering the
data obtained in the validation study (10)(11), the SkinEthic™ HCE EIT has an overall accuracy of 84% (based on 200 chemicals), sensitivity of 95% (based on 97 chemicals), false negative rate of 5% (based on 97 chemicals), specificity of 72% (based on 103 chemicals) and false positive rate of 28% (based on 103 chemicals), when compared to reference in vivo rabbit eye test data (OECD TG 405) (2)(14) classified according to the UN GHS classification system (1).

16. The false negative rates obtained with both RhCE test methods with either substances or mixtures applying their respective established cut-offs are within the overall probability of at least 12% that chemicals identified as UN GHS Category 2 by the in vivo Draize eye test are equally identified as UN GHS No Category in a repeated test due to the method's inherent within-test variability (24). The false positive rates obtained with both RhCE test methods with either substances or mixtures are not critical in the context of this Test Guideline since all test chemicals that produce a tissue viability equal or lower than the established cut-offs (see paragraph 45) will require further testing with other adequate in vitro test methods, or as a last option in rabbits, depending on regulatory requirements, using a sequential testing strategy in a weight-of-evidence approach. These test methods can be used for all types of chemicals, whereby a negative result should be accepted for not classifying a chemical for eye irritation and serious eye damage (UN GHS No Category). The appropriate regulatory authorities should be consulted before using the EpiOcular™ EIT and SkinEthic™ HCE EIT under classification schemes other than UN GHS.

17. A limitation of this Test Guideline is that it does not allow discrimination between eye irritation/reversible effects on the eye (Category 2) and serious eye damage/irreversible effects on the eye (Category 1), nor between eye irritants (optional Category 2A) and mild eye irritants (optional Category 2B), as defined by UN GHS (1). For these purposes, further testing with other suitable test methods is required.

18. The validation study demonstrated that RhCE test methods are able to correctly predict chemicals requiring classification for serious eye damage/eye irritation independently of the types of ocular effects observed in vivo (i.e., corneal, iridal and conjunctival injuries) (8)(10)(11)(13). In this respect, it should be noted that effects on the iris are of lesser importance for classification of chemicals according to UN GHS (24)(25). In fact, iritis on its own rarely drives the UN GHS classification of chemicals in vivo (both Category 1 and Category 2) (1.8-3.1% of the chemicals) since the great majority of the test chemicals that cause classifiable effects to the iris also cause classifiable corneal opacity (24).

19. The term "test chemical" is used in this Test Guideline to refer to what is being tested¹ and is not related to the applicability of the RhCE test method to the testing of substances and/or mixtures.

PRINCIPLE OF THE TEST

20. The test chemical is applied topically to a minimum of two three-dimensional RhCE tissue constructs and tissue viability is measured following exposure and a post-treatment incubation period. The RhCE tissues are reconstructed from primary human epidermal keratinocytes or human immortalized corneal epithelial cells, which have been cultured for several days to form a stratified, highly differentiated squamous epithelium morphologically similar to that found in the human cornea. The EpiOcular™ RhCE tissue construct consists of at least 3 viable layers of cells and a non-keratinized surface, showing a corneal-like structure analogous to that found in vivo. The SkinEthic™ HCE RhCE tissue construct consists of at least 4 viable layers of cells including columnar basal cells, transitional wing cells and superficial squamous cells similar to that of the normal human corneal epithelium (20)(26).

¹ In June 2013, the Joint Meeting agreed that where possible, a more consistent use of the term “test chemical” describing what is being tested should now be applied in new and updated Test Guidelines.
21. Chemical-induced serious eye damage/eye irritation, manifested in vivo mainly by corneal opacity, iritis, conjunctival redness and/or conjunctival chemosis, is the result of a cascade of events beginning with penetration of the chemical through the cornea and/or conjunctiva and production of damage to the cells. Cell damage can occur by several modes of action, including; cell membrane lysis (e.g., by surfactants, organic solvents); coagulation of macromolecules (particularly proteins) (e.g., by surfactants, organic solvents, alkalis and acids); saponification of lipids (e.g., by alkalis); and alklylation or other covalent interactions with macromolecules (e.g., by bleaches, peroxides and alkylators) (15)(27)(28). However, it has been shown that cytotoxicity plays an important role, if not the primary, mechanistic role in determining the overall serious eye damage/eye irritation response of a chemical regardless of the physicochemical processes underlying tissue damage (29)(30). Moreover, the serious eye damage/eye irritation potential of a chemical is principally determined by the extent of initial injury (31), which correlates with the extent of cell death (29) and with the extent of the subsequent responses and eventual outcomes (32). Thus, slight irritants generally only affect the superficial corneal epithelium, the mild and moderate irritants damage principally the epithelium and superficial stroma and the severe irritants damage the epithelium, deep stroma and at times the corneal endothelium (30)(33). The measurement of viability of the RhCE tissue construct after topical exposure to a test chemical to identify chemicals not requiring classification for serious eye damage/eye irritancy (UN GHS No Category) is based on the assumption that all chemicals inducing serious eye damage or eye irritation will induce cytotoxicity in the corneal epithelium and/or conjunctiva.

22. RhCE tissue viability is classically measured by enzymatic conversion of the vital dye MTT [3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide; Thiazolyl blue tetrazolium bromide; CAS number 298-93-1] by the viable cells of the tissue into a blue MTT formazan salt that is quantitatively measured after extraction from tissues (16). Chemicals not requiring classification and labelling according to UN GHS (No Category) are identified as those that do not decrease tissue viability below a defined threshold (i.e., tissue viability > 60%, in SkinEthic™ HCE EITL and EpiOcular™ EIT, or > 50%, in SkinEthic™ HCE EITS) (see paragraph 45).

DEMONSTRATION OF PROFICIENCY

23. Prior to routine use of RhCE test methods for regulatory purposes, laboratories should demonstrate technical proficiency by correctly predicting the fifteen proficiency chemicals listed in Table 1. These chemicals were selected from the chemicals used in the validation studies of the VRMs (8)(10)(11)(13). The selection includes, to the extent possible, chemicals that: (i) cover different physical states; (ii) cover the full range of in vivo serious eye damage/eye irritation responses based on high quality results obtained in the reference in vivo rabbit eye test (OECD TG 405) (2)(14) and the UN GHS classification system (i.e., Categories 1, 2A, 2B, or No Category) (1); (iii) cover the various in vivo drivers of classification (24)(25); (iv) are representative of the chemical classes used in the validation study (8)(10)(11)(13); (v) cover a good and wide representation of organic functional groups (8)(10)(11)(13); (vi) have chemical structures that are well-defined (8)(10)(11)(13); (vii) are coloured and/or direct MTT reducers; (viii) produced reproducible results in RhCE test methods during their validations; (ix) were correctly predicted by RhCE test methods during their validations; (x) cover the full range of in vitro responses based on high quality RhCE test methods data (0 to 100% viability); (xi) are commercially available; and (xii) are not associated with prohibitive acquisition and/or disposal costs. In situations where a listed chemical is unavailable or cannot be used for other justified reasons, another chemical fulfilling the criteria described above, e.g. from the chemicals used in the validation of the VRM, could be used. Such deviations should however be justified.
Table 1: List of proficiency chemicals

<table>
<thead>
<tr>
<th>Chemical Name</th>
<th>CASRN</th>
<th>Organic Functional Group</th>
<th>Physical State</th>
<th>VRM1 viability (%)</th>
<th>VRM2 viability (%)</th>
<th>VRM Prediction</th>
<th>MTT Reducer</th>
<th>Colour interf.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Methylthioglycolate</td>
<td>2365-48-2</td>
<td>Carboxylic acid ester; Thioalcohol</td>
<td>L</td>
<td>10.9±6.4</td>
<td>5.5±7.4</td>
<td>No prediction can be made</td>
<td>Y (strong)</td>
<td>N</td>
</tr>
<tr>
<td>Hydroxyethyl acrylate</td>
<td>818-61-1</td>
<td>Acrylate; Alcohol</td>
<td>L</td>
<td>7.5±4.7</td>
<td>1.6±1.0</td>
<td>No prediction can be made</td>
<td>N</td>
<td>N</td>
</tr>
<tr>
<td>2,5-Dimethyl-2,5-hexanediol</td>
<td>110-03-2</td>
<td>Alcohol</td>
<td>S</td>
<td>2.3±0.2</td>
<td>0.2±0.1</td>
<td>No prediction can be made</td>
<td>N</td>
<td>N</td>
</tr>
<tr>
<td>Sodium oxalate</td>
<td>62-76-0</td>
<td>Oxocarboxylic acid</td>
<td>S</td>
<td>29.0±1.2</td>
<td>5.3±4.1</td>
<td>No prediction can be made</td>
<td>N</td>
<td>N</td>
</tr>
</tbody>
</table>

**In Vivo Category 1**

| 2,4,11,13-Tetraazatetradecane-diimidamide, N,N',bis(4-chlorophenyl)-3,12-dimino-,- di-D-gluconate (20%, aqueous) | 18472-51-0 | Aromatic heterocyclic halide; Aryl halide; Dihydroxyl group; Guanidine | L | 4.0±1.1 | 1.3±0.6 | No prediction can be made | N | Y (weak) |
| Sodium benzoate | 532-32-1 | Aryl; Carboxylic acid | S | 3.5±2.6 | 0.6±0.1 | No prediction can be made | N | N |

**In Vivo Category 2A**

| Diethyl toluamide | 134-62-3 | Benzamide | L | 15.6±6.3 | 2.8±0.9 | No prediction can be made | N | N |

**In Vivo Category 2B**

| 2,2-Dimethyl-3-methylenebicyclo [2.2.1] heptane | 79-92-5 | Alkane, branched with tertiary carbon; Alkene; Bicycloheptane; Bridged-ring carbocycles; Cycloalkane | S | 4.7±1.5 | 15.8±1.1 | No prediction can be made | N | N |

**In Vivo No Category**

| 1-Ethyl-3-methylimidazolium ethylsulphate | 342573-75-5 | Alkox; Ammonium salt; Aryl; Imidazole; Sulphate | L | 79.9±6.4 | 79.4±6.2 | No Cat | N | N |
| Dicaprylyl ether | 629-82-3 | Alkox; Ether | L | 97.8±4.3 | 95.2±3.0 | No Cat | N | N |
| Piperonyl butoxide | 51-03-6 | Alkox; Benzodioxole; Benzyl; Ether | L | 104.2±4.2 | 96.5±3.5 | No Cat | N | N |
| Polyethylene glycol (PEG–40) hydrogenated castor oil | 61788-85-0 | Acylal; Alcohol; Allyl; Ether | Viscous | 77.6±5.4 | 89.1±2.9 | No Cat | N | N |
### Table

<table>
<thead>
<tr>
<th>Chemical Name</th>
<th>CASRN</th>
<th>Organic Functional Group¹</th>
<th>Physical State</th>
<th>VRM1 viability (%)(²)</th>
<th>VRM2 viability (%)(³)</th>
<th>VRM Prediction</th>
<th>MTT Reducer</th>
<th>Colour interf.</th>
</tr>
</thead>
<tbody>
<tr>
<td>1-(4-Chlorophenyl)-3-(3,4-dichlorophenyl) urea</td>
<td>101-20-2</td>
<td>Aromatic heterocyclic halide; Aryl halide; Urea derivatives</td>
<td>S</td>
<td>106.7±5.3</td>
<td>101.9±6.6</td>
<td>No Cat</td>
<td>N</td>
<td>N</td>
</tr>
<tr>
<td>2,2'-Methylene-bis-(6-(2H-benzo[1,3]diazol-2-yl)-4-(1,1,3,3-tetramethylbutyl)-phenol)</td>
<td>103597-45-1</td>
<td>Alkane branched with quaternary carbon; Fused carboxylic aromatic; Fused saturated heterocycles; Precursors quinoid compounds; tert-Butyl</td>
<td>S</td>
<td>102.7±13.4</td>
<td>97.7±5.6</td>
<td>No Cat</td>
<td>N</td>
<td>N</td>
</tr>
<tr>
<td>Potassium tetrafluoroborate</td>
<td>14075-53-7</td>
<td>Inorganic Salt</td>
<td>S</td>
<td>88.6±3.3</td>
<td>92.9±5.1</td>
<td>No Cat</td>
<td>N</td>
<td>N</td>
</tr>
</tbody>
</table>

Abbreviations: CASRN = Chemical Abstracts Service Registry Number; UN GHS = United Nations Globally Harmonized System of Classification and Labelling of Chemicals (1); VRM1 = Validated Reference Method, EpiOcular™ EIT; VRM2 = Validated Reference Method, SkinEthic™ HCE EIT; Colour interf. = colour interference with the standard absorbance (Optical Density (OD)) measurement of MTT formazan.

¹ Organic functional group assigned according to an OECD Toolbox 3.1 nested analysis (8)(13).
² Based on results obtained for EpiOcular™ EIT in the EURL ECVAM/Cosmetics Europe Eye Irritation Validation Study (EIVS) (8).
³ Based on results obtained for SkinEthic™ HCE EIT in the Eye Irritation Test (EIT) Validation Study (10)(11).
⁴ Based on results from the in vivo rabbit eye test (OECD TG 405) (2)(14) and using the UN GHS (1).
⁵ Based on results obtained in the CEFIC CONsortium for in vitro Eye Irritation testing strategy (CON4EI) Study.

### Procedure

#### 24. As part of the proficiency testing, it is recommended that users verify the barrier properties of the tissues after receipt as specified by the RhCE tissue construct producer (see paragraphs 26, 28 and 31). This is particularly important if tissues are shipped over long distance / time periods. Once a test method has been successfully established and proficiency in its use has been acquired and demonstrated, such verification will not be necessary on a routine basis. However, when using a test method routinely, it is recommended to continue to assess the barrier properties at regular intervals.

#### 25. The test methods currently covered by this Test Guideline are the scientifically valid EpiOcular™ EIT and SkinEthic™ HCE EIT (9)(12)(13), referred to as the Validated Reference Method (VRM1 and VRM2, respectively). The Standard Operating Procedures (SOP) for the RhCE test methods are available and should be employed when implementing and using the test methods in a laboratory (34)(35). The following paragraphs and Annex II describe the main components and procedures of the RhCE test methods.
RtHCE TEST METHOD COMPONENTS

General conditions

26. Relevant human-derived cells should be used to reconstruct the cornea-like epithelium three-dimensional tissue, which should be composed of progressively stratified but not cornified cells. The RhCE tissue construct is prepared in inserts with a porous synthetic membrane through which nutrients can pass to the cells. Multiple layers of viable, non-keratinized epithelial cells should be present in the reconstructed cornea-like epithelium. The RhCE tissue construct should have the epithelial surface in direct contact with air so as to allow for direct topical exposure of test chemicals in a fashion similar to how the corneal epithelium would be exposed in vivo. The RhCE tissue construct should form a functional barrier with sufficient robustness to resist rapid penetration of cytotoxic benchmark substances, e.g., Triton X-100 or sodium dodecyl sulphate (SDS). The barrier function should be demonstrated and may be assessed by determination of either the exposure time required to reduce tissue viability by 50% (ET<sub>50</sub>) upon application of a benchmark substance at a specified, fixed concentration (e.g., 100 µL of 0.3% (v/v) Triton X-100), or the concentration at which a benchmark substance reduces the viability of the tissues by 50% (IC<sub>50</sub>) following a fixed exposure time (e.g., 30 minutes treatment with 50 µL SDS) (see paragraph 31). The containment properties of the RhCE tissue construct should prevent the passage of test chemical around the edge of the viable tissue, which could lead to poor modelling of corneal exposure. The human-derived cells used to establish the RhCE tissue construct should be free of contamination by bacteria, viruses, mycoplasma, and fungi. The sterility of the tissue construct is then checked for absence of contamination by fungi and bacteria.

Functional conditions

Viability

27. The assay used for quantifying tissue viability is the MTT assay (16). Viable cells of the RhCE tissue construct reduce the vital dye MTT into a blue MTT formazan precipitate, which is then extracted from the tissue using isopropanol (or a similar solvent). The extracted MTT formazan may be quantified using either a standard absorbance (Optical Density (OD)) measurement or an HPLC/UPLC-spectrophotometry procedure (36). The OD of the extraction solvent alone should be sufficiently small, i.e., OD < 0.1. Users of the RhCE tissue construct should ensure that each batch of the RhCE tissue construct used meets defined criteria for the negative control. Acceptability ranges for the negative control OD values for the VRMs are given in Table 2. An HPLC/UPLC-spectrophotometry user should use the negative control OD ranges provided in Table 2 as the acceptance criterion for the negative control. It should be documented that the tissues treated with the negative control substance are stable in culture (provide similar tissue viability measurements) for the duration of the test exposure period. A similar procedure should be followed by the tissue producer as part of the quality control tissue batch release, but in this case different acceptance criteria than those specified in Table 2 may apply. An acceptability range (upper and lower limit) for the negative control OD values (in the QC test method conditions) should be established by the RhCE tissue construct developer/supplier.

<table>
<thead>
<tr>
<th>Test Method</th>
<th>Lower acceptance limit</th>
<th>Upper acceptance limit</th>
</tr>
</thead>
<tbody>
<tr>
<td>EpiOcular™ EIT (OCL-200) – VRM1 (for both the liquids and the solids protocols)</td>
<td>&gt; 0.8&lt;sup&gt;1&lt;/sup&gt;</td>
<td>&lt; 2.5</td>
</tr>
<tr>
<td>SkinEthic™ HCE EIT (HCE/S) – VRM2 (for both the liquids and the solids protocols)</td>
<td>&gt; 1 .0&lt;sup&gt;1&lt;/sup&gt;</td>
<td>≤ 2.5</td>
</tr>
</tbody>
</table>
This acceptance limit considers the possibility of extended shipping/storage time (e.g., > 4 days), which has been shown not to impact on the performance of the test method (37).

**Barrier function**

28. The RhCE tissue construct should be sufficiently thick and robust to resist the rapid penetration of cytotoxic benchmark substances, as estimated e.g. by ET\textsubscript{50} (Triton X-100) or by IC\textsubscript{50} (SDS) (Table 3). The barrier function of each batch of the RhCE tissue construct used should be demonstrated by the RhCE tissue construct developer/vendor upon supply of the tissues to the end user (see paragraph 31).

**Morphology**

29. Histological examination of the RhCE tissue construct should demonstrate human cornea-like epithelium structure (including at least 3 layers of viable epithelial cells and a non-keratinized surface). For the VRMs, appropriate morphology has been established by the developer/supplier and therefore does not need to be demonstrated again by a test method user for each tissue batch used.

**Reproducibility**

30. The results of the positive and negative controls of the test method should demonstrate reproducibility over time.

**Quality control (QC)**

31. The RhCE tissue construct should only be used if the developer/supplier demonstrates that each batch of the RhCE tissue construct used meets defined production release criteria, among which those for viability and barrier function (see paragraph 28) are the most relevant. An acceptability range (upper and lower limits) for the barrier functions as measured by the ET\textsubscript{50} or IC\textsubscript{50} (see paragraphs 26 and 27) should be established by the RhCE tissue construct developer/supplier. The ET\textsubscript{50} and IC\textsubscript{50} acceptability range used as QC batch release criterion by the developer/supplier of the RhCE tissue constructs (used in the VRMs) is given in Table 3. Data demonstrating compliance with all production release criteria should be provided by the RhCE tissue construct developer/supplier to the test method users so that they are able to include this information in the test report. Only results produced with tissues fulfilling all of these production release criteria can be accepted for reliable prediction of chemicals not requiring classification and labelling for eye irritation or serious eye damage in accordance with UN GHS.

<table>
<thead>
<tr>
<th>Test Method</th>
<th>Lower acceptance limit</th>
<th>Upper acceptance limit</th>
</tr>
</thead>
<tbody>
<tr>
<td>EpiOcular™ EIT (OCL-200) – VRM1 (100 µL of 0.3% (v/v) Triton X-100)</td>
<td>ET\textsubscript{50} = 12.2 min</td>
<td>ET\textsubscript{50} = 37.5 min</td>
</tr>
<tr>
<td>SkinEthic™ HCE EIT (HCE/S) – VRM2 (30 minutes treatment with 50 µL SDS)</td>
<td>IC\textsubscript{50} = 1 mg/mL</td>
<td>IC\textsubscript{50} = 3.2 mg/mL</td>
</tr>
</tbody>
</table>

**Application of the Test Chemical and Control Substances**

32. At least two tissue replicates should be used for each test chemical and each control substance in each run. Two different treatment protocols are used, one for liquid test chemicals and one for solid test chemicals.
chemicals (34)(35). Depending on the methods, the epidermis surface should be moistened with calcium and magnesium-free Dulbecco’s Phosphate Buffered Saline (Ca\(^{2+}/\)Mg\(^{2+}\)-free DPBS) before application of test chemicals, to mimic the wet conditions of human eye. The treatment of the tissues is initiated with exposure to the test chemical(s) and control substances. In either case a sufficient amount of test chemical or control substance should be applied to uniformly cover the epithelial surface while avoiding an infinite dose (see paragraphs 33 and 34). According to the test procedures, it is essential that the tissue viability measurements are not made immediately after exposure to the test chemical, but rather after a sufficiently long post-exposure incubation period (in fresh medium) after the test chemical has been rinsed from the tissue (Annex II). This period allows both for recovery from weak cytotoxic effects and for appearance of clear cytotoxic effects.

33. Test chemicals that can be pipetted at 37°C or lower temperatures (using a positive displacement pipette, if needed) are treated as liquids in the VRMs, otherwise they should be treated as solids (see paragraph 34). In the VRMs, liquid test chemical are evenly spread over the tissue surface (i.e. a minimum of 60 µL/cm\(^2\) application) (see e.g. references 34-35, Annex II). Tissues treated with liquid test chemicals and with control substances tested concurrently to liquid test chemicals are incubated at standard culture conditions. At the end of the exposure period, the test chemical and control substances should be carefully removed from the tissue surface by extensive rinsing with Ca\(^{2+}/\)Mg\(^{2+}\)-free DPBS at room temperature. This rinsing step is followed by a post-exposure immersion in fresh medium at room temperature (to remove any test chemical absorbed into the tissue) for both VRMs, in addition of with a post-exposure incubation in fresh medium at standard culture conditions for VRM1 only, prior to performing the MTT assay (34)(35) (see paragraph 36).

34. Test chemicals that cannot be pipetted at temperatures up to 37°C are treated as solids in the VRMs. The amount of test chemical applied should be sufficient to cover the entire surface of the tissue, i.e. a minimum of 60 mg/cm\(^2\) application should be used (Annex II). Whenever possible, solids should be tested as a fine powder. Tissues treated with solid test chemicals and with control substances tested concurrently are incubated at standard culture conditions. At the end of the exposure period, the test chemical and control substances should be carefully removed from the tissue surface by extensive rinsing with Ca\(^{2+}/\)Mg\(^{2+}\)-free DPBS at room temperature. This rinsing step is followed by a post-exposure immersion in fresh medium at room temperature (to remove any test chemical absorbed into the tissue) and a post-exposure incubation in fresh medium at standard culture conditions, prior to performing the MTT assay (34)(35) (see paragraph 36).

35. Concurrent negative and positive controls should be included in each run to demonstrate that the viability (determined with the negative control) and the sensitivity (determined with the positive control) of the tissues are within acceptance ranges defined based on historical data. The concurrent negative control also provides the baseline (100% tissue viability) to calculate the relative percent viability of the tissues treated with the test chemical (%Viability\(_{\text{tissue}}\)). The recommended positive control substance to be used with the VRMs is neat methyl acetate (CAS No. 79-20-9, commercially available from e.g., Sigma-Aldrich, Cat# 186325; liquid). The recommended negative control substances to be used with the VRM1 and VRM2 are ultrapure H\(_2\)O and Ca\(^{2+}/\)Mg\(^{2+}\)-free DPBS, respectively. These were the control substances used in the validation studies of the VRMs and are those for which most historical data exist. The use of suitable alternative positive or negative control substances should be scientifically and adequately justified. For controls performed concurrently to test chemicals, the negative control and positive control substances should be applied to the tissues exactly as for the liquid test chemicals (as see paragraph 33). This should be followed by the relevant treatment exposure, rinsing, post-exposure immersion and post-exposure incubation (where applicable) as described for controls run concurrently to liquid test chemicals (see paragraph 33) or for controls run concurrently to solid test chemicals (see paragraph 34), prior to performing the MTT assay (see paragraph36) (34)(35). One single set of negative and positive controls is sufficient for all test chemicals of the same physical state (liquids or solids) included in the same run.
**Tissue Viability Measurements**

36. The MTT assay is a standardised quantitative method (16) that should be used to measure tissue viability under this Test Guideline. It is compatible with use in a three-dimensional tissue construct. The MTT assay is performed immediately following the post-exposure incubation period. In the VRMs, the RhCE tissue construct sample is placed in 0.5 mL of MTT solution at 1 mg/mL for appropriate timing at standard culture conditions. The vital dye MTT is reduced into a blue MTT formazan precipitate by the viable cells of the RhCE tissue construct. The precipitated blue MTT formazan product is then extracted from the tissue using appropriate volume of isopropanol (or a similar solvent) (34)(35). Tissues tested with liquid test chemicals should be extracted from both the top and the bottom of the tissues, while tissues tested with solid test chemicals and coloured liquids should be extracted from the bottom of the tissue only (to minimise any potential contamination of the isopropanol extraction solution with any test chemical that may have remained on the tissue). Tissues tested with liquid test chemicals that are not readily washed off may also be extracted from the bottom of the tissue only. The concurrently tested negative and positive control substances should be treated similarly to the tested chemical. The extracted MTT formazan may be quantified either by a standard absorbance (OD) measurement at 570 nm using a filter band pass of maximum ± 30 nm or by using an HPLC/UPLC-spectrophotometry procedure (see paragraph 43) (11)(36).

37. Optical properties of the test chemical or its chemical action on MTT may interfere with the measurement of MTT formazan leading to a false estimate of tissue viability. Test chemicals may interfere with the measurement of MTT formazan by direct reduction of the MTT into blue MTT formazan and/or by colour interference if the test chemical absorbs, naturally or due to treatment procedures, in the same OD range as MTT formazan (i.e., around 570 nm). Pre-checks should be performed before testing to allow identification of potential direct MTT reducers and/or colour interfering chemicals and additional controls should be used to detect and correct for potential interference from such test chemicals (see paragraphs 38-42). This is especially important when a specific test chemical is not completely removed from the RhCE tissue construct by rinsing or when it penetrates the cornea-like epithelium and is therefore present in the RhCE tissue constructs when the MTT assay is performed. For test chemicals absorbing light in the same range as MTT formazan (naturally or after treatment), which are not compatible with the standard absorbance (OD) measurement of MTT formazan due to too strong interference, i.e., strong absorption at 570±30 nm, an HPLC/UPLC-spectrophotometry procedure to measure MTT formazan may be employed (see paragraphs 42 and 43) (11)(36). A detailed description of how to detect and correct for direct MTT reduction and interferences by colouring agents is available in the VRMs SOPs (34)(35). Illustrative flowcharts providing guidance on how to identify and handle direct MTT-reducers and/or colour interfering chemicals for VRM1 and VRM2 are also provided in Annexes III and IV, respectively.

38. To identify potential interference by test chemicals absorbing light in the same range as MTT formazan (naturally or after treatment) and decide on the need for additional controls, the test chemical is added to water and/or isopropanol and incubated for appropriate timings at room temperature (34)(35). If the test chemical in water and/or isopropanol absorbs sufficient light in the range of 570±30 nm (Annex III for the VRM1), or a colored solution is obtained (Annex IV for VRM2), the test chemical is presumed to interfere with the standard absorbance (OD) measurement of MTT formazan and further colorant controls should be performed or, alternatively, an HPLC/UPLC-spectrophotometry procedure should be used in which case these controls are not required (see paragraphs 42 and 43 and Annexes III-IV). When performing the standard absorbance (OD) measurement, each interfering test chemical should be applied on at least two viable tissue replicates, which undergo the entire testing procedure but are incubated with medium instead of MTT solution during the MTT incubation step, to generate a non-specific colour in living tissues (NSC<sub>living</sub>) control (34)(35). The NSC<sub>living</sub> control needs to be performed concurrently to the testing of the coloured test chemical and, in case of multiple testing, an independent NSC<sub>living</sub> control needs to be conducted with each test performed (in each run) due to the inherent biological variability of living tissues. True tissue viability is calculated as: the percent tissue viability obtained with living tissues exposed to the interfering test chemical and incubated with MTT solution (%Viability<sub>test</sub>) minus the percent
non-specific colour obtained with living tissues exposed to the interfering test chemical and incubated with medium without MTT, run concurrently to the test being corrected (%NSC\textsubscript{living}), i.e., True tissue viability = \[\%\text{Viability}_{\text{test}} - \%\text{NSC}_{\text{living}}.\]

39. To identify direct MTT reducers, each test chemical should be added to freshly prepared MTT solution. Appropriate amount of test chemical are added to a MTT solution and the mixture is incubated for approximately 3 hours at standard culture conditions (see Annexes III-IV)(34)(35). If the MTT mixture containing the test chemical (or suspension for insoluble test chemicals) turns blue/purple, the test chemical is presumed to directly reduce MTT and a further functional check on non-viable RhCE tissue constructs should be performed, independently of using the standard absorbance (OD) measurement or an HPLC/UPLC-spectrophotometry procedure. This additional functional check employs killed tissues that possess only residual metabolic activity but absorb and retain the test chemical in a similar way as viable tissues. In the VRMs, killed tissues are usually prepared by exposure to low temperature ("freeze-killed"), but may also be prepared by prolonged incubation (e.g., at least 24 hours) in water ("water-killed"). Each MTT reducing test chemical is applied on at least two killed tissue replicates, which undergo the entire testing procedure, to generate a non-specific MTT reduction (NSMTT) control (34)(35). A single NSMTT control is sufficient per test chemical regardless of the number of independent tests/runs performed. True tissue viability is calculated as: the percent tissue viability obtained with living tissues exposed to the MTT reducer (\(\%\text{Viability}_{\text{test}}\)) minus the percent non-specific MTT reduction obtained with the killed tissues exposed to the same MTT reducer, calculated relative to the negative control run concurrently to the test being corrected (%NSMTT), i.e., True tissue viability = \[\%\text{Viability}_{\text{test}} - \%\text{NSMTT}.\]

40. Test chemicals that are identified as producing both colour interference (see paragraph 38) and direct MTT reduction (see paragraph 39) will also require a third set of controls when performing the standard absorbance (OD) measurement, apart from the NSMTT and NSC\textsubscript{living} controls described in the previous paragraphs. This is usually the case with darkly coloured test chemicals absorbing light in the range of 570±30 nm (e.g., blue, purple, black) because their intrinsic colour impedes the assessment of their capacity to directly reduce MTT as described in paragraph 39. This forces the use of NSMTT controls, by default, together with the NSC\textsubscript{living} controls. Test chemicals for which both NSMTT and NSC\textsubscript{living} controls are performed may be absorbed and retained by both living and killed tissues. Therefore, in this case, the NSMTT control may not only correct for potential direct MTT reduction by the test chemical, but also for colour interference arising from the absorption and retention of the test chemical by killed tissues. This could lead to double correction for colour interference since the NSC\textsubscript{living} control already corrects for colour interference arising from the absorption and retention of the test chemical by living tissues. To avoid a possible double correction for colour interference, a third control for non-specific colour in killed tissues (NSC\textsubscript{killed}) needs to be performed (see Annexes III-IV)(34)(35). In this additional control, the test chemical is applied on at least two killed tissue replicates, which undergo the entire testing procedure but are incubated with medium instead of MTT solution during the MTT incubation step. A single NSC\textsubscript{killed} control is sufficient per test chemical regardless of the number of independent tests/runs performed, but should be performed concurrently to the NSMTT control and with the same tissue batch. True tissue viability is calculated as: the percent tissue viability obtained with living tissues exposed to the test chemical (\(\%\text{Viability}_{\text{test}}\)) minus %NSMTT minus %NSC\textsubscript{living} plus the percent non-specific colour obtained with killed tissues exposed to the interfering test chemical and incubated with medium without MTT, calculated relative to the negative control run concurrently to the test being corrected (%NSC\textsubscript{killed}), i.e., True tissue viability = \[\%\text{Viability}_{\text{test}} - \%\text{NSMTT} - \%\text{NSC}_{\text{living}} + \%\text{NSC}_{\text{killed}}.\]

41. It is important to note that non-specific MTT reduction and non-specific colour interferences may increase the OD (when performing standard absorbance measurements) of the tissue extract above the linearity range of the spectrophotometer and that non-specific MTT reduction can also increase the MTT formazan peak area (when performing HPLC/UPLC-spectrophotometry measurements) of the tissue extract above the linearity range of the spectrophotometer. On this basis, it is important for each laboratory to determine the OD/peak area linearity range of their spectrophotometer with e.g., MTT formazan (CAS #
57360-69-7), commercially available from e.g., Sigma-Aldrich (Cat# M2003), before initiating the testing of test chemicals for regulatory purposes.

42. The standard absorbance (OD) measurement using a spectrophotometer is appropriate to assess direct MTT-reducers and colour interfering test chemicals, when the observed interference with the measurement of MTT formazan is not too strong (i.e., the ODs of the tissue extracts obtained with the test chemical without any correction for direct MTT reduction and/or colour interference are within the linear range of the spectrophotometer). Nevertheless, results for test chemicals producing %NSMTT and/or %NSC<sub>living</sub> ≥ 50% (VRM2 for solids’ protocol) or 60% (VRM1, and VRM2 for liquids’ protocol) of the negative control should be taken with caution as this is the established cut-off used in the VRMs to distinguish classified from not classified chemicals (see paragraph 45). Standard absorbance (OD) can however not be measured when the interference with the measurement of MTT formazan is too strong (i.e., leading to uncorrected ODs of the test tissue extracts falling outside of the linear range of the spectrophotometer). Coloured test chemicals or test chemicals that become coloured in contact with water or isopropanol that interfere too strongly with the standard absorbance (OD) measurement of MTT formazan may still be assessed using HPLC/UPLC-spectrophotometry (see Annexes III-IV). This is because the HPLC/UPLC system allows for the separation of the MTT formazan from the chemical before its quantification (36). For this reason, NSC<sub>living</sub> or NSC<sub>killed</sub> controls are never required when using HPLC/UPLC-spectrophotometry, independently of the chemical being tested. NSMTT controls should nevertheless be used if the test chemical is suspected to directly reduce MTT (following the procedure described in paragraph 39). NSMTT controls should also be used with test chemicals having a colour (intrinsic or appearing when in water) that impedes the assessment of their capacity to directly reduce MTT as described in paragraph 39. When using HPLC/UPLC-spectrophotometry to measure MTT formazan, the percent tissue viability is calculated as percent MTT formazan peak area obtained with living tissues exposed to the test chemical relative to the MTT formazan peak obtained with the concurrent negative control. For test chemicals able to directly reduce MTT, true tissue viability is calculated as: %Viability<sub>test minus %NSMTT</sub>, as described in the last sentence of paragraph 39. Finally, it should be noted that direct MTT-reducers or direct MTT-reducers that are also colour interfering, which are retained in the tissues after treatment and reduce MTT so strongly that they lead to ODs (using standard OD measurement) or peak areas (using UPLC/HPLC-spectrophotometry) of the tested tissue extracts that fall outside of the linearity range of the spectrophotometer cannot be assessed with RhCE test methods, although these are expected to occur in only very rare situations.

43. HPLC/UPLC-spectrophotometry may be used with all types of test chemicals (coloured, non-coloured, MTT-reducers and non-MTT reducers) for measurement of MTT formazan (11)(36). Due to the diversity of HPLC/UPLC-spectrophotometry systems, it is not feasible for each user to establish the exact same system conditions. As such, qualification of the HPLC/UPLC-spectrophotometry system should be demonstrated before its use to quantify MTT formazan from tissue extracts by meeting the acceptance criteria for a set of standard qualification parameters based on those described in the U.S. Food and Drug Administration guidance for industry on bioanalytical method validation (36)(38). These key parameters and their acceptance criteria are shown in Annex V. Once the acceptance criteria defined in Annex V have been met, the HPLC/UPLC-spectrophotometry system is considered qualified and ready to measure MTT formazan under the experimental conditions described in this Test Guideline.

Acceptance Criteria

44. For each run using RhCE tissue batches that met the quality control (see paragraph 31), tissues treated with the negative control substance should exhibit OD reflecting the quality of the tissues that followed shipment, receipt steps and all protocol processes and should not be outside the historically established boundaries described in Table 2 (see paragraph 27). Similarly, tissues treated with the positive control substance, i.e., methyl acetate, should show a mean tissue viability < 50% relative to the negative control in the VRM1 with either the liquids’ or the solids’ protocols, and ≤ 30% or ≤ 20% relative to the negative control (for liquid test chemicals and solid test chemicals respectively) for VRM2., thus reflecting
the ability of the tissues to respond to an irritant test chemical under the conditions of the test method (34)(35). The variability between tissue replicates of test chemicals and control substances should fall within the accepted limits (i.e., the difference of viability between two tissue replicates should be less than 20% or the SD between three tissue replicates should not exceed 18%). If either the negative control or positive control included in a run is outside of the accepted ranges, the run is considered "non-qualified" and should be repeated. If the variability between tissue replicates of a test chemical is outside of the accepted range, the test must be considered "non-qualified" and the test chemical should be re-tested.

Interpretation of Results and Prediction Model

45. The OD values/peak areas obtained with the replicate tissue extracts for each test chemical should be used to calculate the mean percent tissue viability (mean between tissue replicates) normalised to the negative control, which is set at 100%. The percentage tissue viability cut-off value for identifying test chemicals not requiring classification for eye irritation or serious eye damage (UN GHS No Category) is given in Table 4. Results should thus be interpreted as follows:

- The test chemical is identified as not requiring classification and labelling according to UN GHS (No Category) if the mean percent tissue viability after exposure and post-exposure incubation is more than (>), the established percentage tissue viability cut-off value, as shown in Table 4. In this case no further testing in other test methods is required.

- The test chemical is identified as potentially requiring classification and labelling according to UN GHS (Category 2 or Category 1) if the mean percent tissue viability after exposure and post-exposure incubation is less than or equal (≤) to the established percentage tissue viability cut-off value, no prediction can be made, as shown in Table 4. When the final mean percent tissue viability is less than or equal (≤) to the established cut-off value % further testing with other test methods will be required because RhCE test methods show a certain number of false positive results (see paragraphs 14-15) and cannot resolve between UN GHS Categories 1 and 2 (see paragraph 17).

Table 4: Prediction Models according to UN GHS classification

<table>
<thead>
<tr>
<th>VRM</th>
<th>No Category</th>
<th>No prediction can be made</th>
</tr>
</thead>
<tbody>
<tr>
<td>EpiOcular™ EIT (for both protocols)</td>
<td>Mean tissue viability &gt; 60%</td>
<td>Mean tissue viability ≤ 60%</td>
</tr>
<tr>
<td>SkinEthic™ HCE EIT (for the liquids’ protocol)</td>
<td>Mean tissue viability &gt; 60%</td>
<td>Mean tissue viability ≤ 60%</td>
</tr>
<tr>
<td>SkinEthic™ HCE EIT (for the solids’ protocol)</td>
<td>Mean tissue viability &gt; 50%</td>
<td>Mean tissue viability ≤ 50%</td>
</tr>
</tbody>
</table>

46. A single test composed of at least two tissue replicates should be sufficient for a test chemical when the result is unequivocal. However, in cases of borderline results, such as non-concordant replicate measurements and/or mean percent tissue viability equal to 50±5% (VRM2 for solids’ protocol) or 60±5% (VRM1, and VRM2 for liquids’ protocol), a second test should be considered, as well as a third one in case of discordant results between the first two tests.

47. Different percentage tissue viability cut-off values distinguishing classified from non-classified test chemicals may be considered for specific types of mixtures, where appropriate and justifiable, in order to increase the overall performance of the test method for those types of mixtures (see paragraph 14).
Benchmark chemicals may be useful for evaluating the serious eye damage/eye irritation potential of unknown chemicals of a specific chemical or product class, or for evaluating the relative ocular toxicity potential of a classified chemical within a specific range of positive responses.

DATA AND REPORTING

Data

48. Data from individual replicate tissues in a run (e.g., OD values/MTT formazan peak areas and calculated percent tissue viability data for the test chemical and controls, and the final RhCE test method prediction) should be reported in tabular form for each test chemical, including data from repeat tests, as appropriate. In addition, mean percent tissue viability and Diff (if n=2 replicate tissues) or SD (if n≥3 replicate tissues) for each individual test chemical and control should be reported. Any observed interferences of a test chemical with the measurement of MTT formazan through direct MTT reduction and/or coloured interference should be reported for each tested chemical.

Test Report

49. The test report should include the following information:

Test Chemical

- Mono-constituent substance
  - Chemical identification, such as IUPAC or CAS name(s), CAS registry number(s), SMILES or InChI code, structural formula, and/or other identifiers;
  - Physical state, volatility, pH, LogP, molecular weight, chemical class, and additional relevant physicochemical properties relevant to the conduct of the study, to the extent available;
  - Purity, chemical identity of impurities as appropriate and practically feasible, etc.;
  - Treatment prior to testing, if applicable (e.g., warming, grinding);
  - Storage conditions and stability to the extent available.

- Multi-constituent substance, UVCB and mixture
  - Characterisation as far as possible by e.g., chemical identity (see above), purity, quantitative occurrence and relevant physicochemical properties (see above) of the constituents, to the extent available;
  - Physical state and additional relevant physicochemical properties relevant to the conduct of the study, to the extent available;
  - Purity, chemical identity of impurities as appropriate and practically feasible, etc.;
  - Treatment prior to testing, if applicable (e.g., warming, grinding);
  - Storage conditions and stability to the extent available.

Positive and Negative Control Substances

- Chemical identification, such as IUPAC or CAS name(s), CAS registry number(s), SMILES or InChI code, structural formula, and/or other identifiers;
- Physical state, volatility, molecular weight, chemical class, and additional relevant physicochemical properties relevant to the conduct of the study, to the extent available;
- Purity, chemical identity of impurities as appropriate and practically feasible, etc.;
- Treatment prior to testing, if applicable (e.g., warming, grinding);
- Storage conditions and stability to the extent available;
- Justification for the use of a different negative control than ultrapure H₂O or Ca²⁺/Mg²⁺-free DPBS, if applicable;
- Justification for the use of a different positive control than neat methyl acetate, if applicable;
- Reference to historical positive and negative control results demonstrating suitable run acceptance criteria.

Information Concerning the Sponsor and the Test Facility
- Name and address of the sponsor, test facility and study director.

RhCE Tissue Construct and Protocol Used (providing rationale for the choices, if applicable)

Test Method Conditions
- RhCE tissue construct used, including batch number;
- Wavelength and band pass (if applicable) used for quantifying MTT formazan, and linearity range of measuring device (e.g., spectrophotometer);
- Description of the method used to quantify MTT formazan;
- Description of the HPLC/UPLC-spectrophotometry system used, if applicable;
- Complete supporting information for the specific RhCE tissue construct used including its performance. This should include, but is not limited to:
  i) Viability quality control (supplier)
  ii) Viability under test method conditions (user);
  iii) Barrier function quality control;
  iv) Morphology, if available;
  v) Reproducibility and predictive capacity;
  vi) Other quality controls (QC) of the RhCE tissue construct, if available;
- Reference to historical data of the RhCE tissue construct. This should include, but is not limited to: Acceptability of the QC data with reference to historical batch data;
- Statement that the testing facility has demonstrated proficiency in the use of the test method before routine use by testing of the proficiency chemicals;

Run and Test Acceptance Criteria
- Positive and negative control means and acceptance ranges based on historical data;
- Acceptable variability between tissue replicates for positive and negative controls;
- Acceptable variability between tissue replicates for the test chemical;

Test Procedure
Draft revised TG 492, December 2016

- Details of the test procedure used;
- Doses of test chemical and control substances used;
- Duration and temperature of exposure, post-exposure immersion and post-exposure incubation periods (where applicable);
- Description of any modifications to the test procedure;
- Indication of controls used for direct MTT-reducers and/or colouring test chemicals, if applicable;
- Number of tissue replicates used per test chemical and controls (positive control, negative control, NSMTT, NSC_living and NSC_killed, if applicable);

Results

- Tabulation of data from individual test chemicals and control substances for each run (including repeat experiments where applicable) and each replicate measurement, including OD value or MTT formazan peak area, percent tissue viability, mean percent tissue viability, Difference between tissue replicates or SD, and final prediction;
- If applicable, results of controls used for direct MTT-reducers and/or coloured test chemicals, including OD value or MTT formazan peak area, %NSMTT, %NSC_living, %NSC_killed, Difference between tissue replicates or SD, final correct percent tissue viability, and final prediction;
- Results obtained with the test chemical(s) and control substances in relation to the define run and test acceptance criteria;
- Description of other effects observed, e.g., coloration of the tissues by a coloured test chemical;

Discussion of the Results

Conclusion
LITERATURE


9) EC EURL ECVAM. (2016). ESAC Opinion No. 2014-03 based on the ESAC Scientific Peer Review of the ECVAM Eye Irritation Validation Study (EIVS) and a related Cosmetics Europe study on HPLC/UPLC-photometry as an alternative endpoint detection system for formazan reaction product. EUR 28125 EN; doi 10.2787/043697. Available at:


Draft revised TG 492, December 2016


ANNEX I

DEFINITIONS

Accuracy: The closeness of agreement between test method results and accepted reference values. It is a measure of test method performance and one aspect of “relevance.” The term is often used interchangeably with “concordance”, to mean the proportion of correct outcomes of a test method (16).

Benchmark chemical: A chemical used as a standard for comparison to a test chemical. A benchmark chemical should have the following properties: (i) consistent and reliable source(s); (ii) structural, functional and/or chemical or product class similarity to the chemical(s) being tested; (iii) known physicochemical characteristics; (iv) supporting data on known effects; and (v) known potency in the range of the desired response.

Bottom-Up approach: Step-wise approach used for a test chemical suspected of not requiring classification and labelling for eye irritation or serious eye damage, which starts with the determination of chemicals not requiring classification and labelling (negative outcome) from other chemicals (positive outcome).

Chemical: A substance or mixture.

Concordance: See "Accuracy".

Cornea: The transparent part of the front of the eyeball that covers the iris and pupil and admits light to the interior.

CV: Coefficient of Variation.

Dev: Deviation.

EIT: Eye Irritation Test.

EITL: Eye Irritation Test for Liquid/Viscous chemicals.

EITS: Eye Irritation Test for Solid chemicals.

EURO ECVAM: European Union Reference Laboratory for Alternatives to Animal Testing.

Eye irritation: Production of changes in the eye following the application of a test chemical to the anterior surface of the eye, which are fully reversible within 21 days of application. Interchangeable with “Reversible effects on the eye” and with “UN GHS Category 2” (1).

ET_{50}: Exposure time required to reduce tissue viability by 50% upon application of a benchmark chemical at a specified, fixed concentration.
False negative rate: The proportion of all positive substances falsely identified by a test method as negative. It is one indicator of test method performance.

False positive rate: The proportion of all negative substances that are falsely identified by a test method as positive. It is one indicator of test method performance.

Hazard: Inherent property of an agent or situation having the potential to cause adverse effects when an organism, system or (sub) population is exposed to that agent.

HCE: SkinEthic™ Human Corneal Epithelium.

HPLC: High Performance Liquid Chromatography.

IC\textsubscript{50}: Concentration at which a benchmark chemical reduces the viability of the tissues by 50\% following a fixed exposure time (e.g., 30 minutes treatment with SDS).

Infinite dose: Amount of test chemical applied to the RhCE tissue construct exceeding the amount required to completely and uniformly cover the epithelial surface.

Irreversible effects on the eye: See “Serious eye damage”.

LLOQ: Lower Limit of Quantification.

LogP: Logarithm of the octanol-water partitioning coefficient.

Mixture: A mixture or a solution composed of two or more substances in which they do not react (1).

Mono-constituent substance: A substance, defined by its quantitative composition, in which one main constituent is present to at least 80\% (w/w).

Multi-constituent substance: A substance, defined by its quantitative composition, in which more than one main constituent is present in a concentration $\geq$ 10\% (w/w) and < 80\% (w/w). A multi-constituent substance is the result of a manufacturing process. The difference between mixture and multi-constituent substance is that a mixture is obtained by blending of two or more substances without chemical reaction. A multi-constituent substance is the result of a chemical reaction.

MTT: 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide; Thiazolyl blue tetrazolium bromide.

Negative control: A sample containing all components of a test system and treated with a substance known not to induce a positive response in the test system. This sample is processed with test chemical-treated samples and other control samples and is used to determine 100\% tissue viability.

Not Classified: Chemicals that are not classified for Eye irritation (UN GHS Category 2, 2A, or 2B) or Serious eye damage (UN GHS Category 1). Interchangeable with “UN GHS No Category”.

NSC\textsubscript{killed}: Non-Specific Colour in killed tissues.

NSC\textsubscript{living}: Non-Specific Colour in living tissues.

NSMTT: Non-Specific MTT reduction.
**OD:** Optical Density.

**Performance standards:** Standards, based on a validated test method which was considered scientifically valid, that provide a basis for evaluating the comparability of a proposed test method that is mechanistically and functionally similar. Included are: (i) essential test method components; (ii) a minimum list of Reference Chemicals selected from among the chemicals used to demonstrate the acceptable performance of the validated test method; and (iii) the comparable levels of accuracy and reliability, based on what was obtained for the validated test method, that the proposed test method should demonstrate when evaluated using the minimum list of Reference Chemicals (16).

**Positive control:** A sample containing all components of a test system and treated with a substance known to induce a positive response in the test system. This sample is processed with test chemical-treated samples and other control samples. To ensure that variability in the positive control response across time can be assessed, the magnitude of the positive response should not be excessive.

**Relevance:** Description of relationship of the test to the effect of interest and whether it is meaningful and useful for a particular purpose. It is the extent to which the test correctly measures or predicts the biological effect of interest. Relevance incorporates consideration of the accuracy (concordance) of a test method (16).

**Reliability:** Measures of the extent that a test method can be performed reproducibly within and between laboratories over time, when performed using the same protocol. It is assessed by calculating intra- and inter-laboratory reproducibility and intra-laboratory repeatability (16).

**Replacement test:** A test which is designed to substitute for a test that is in routine use and accepted for hazard identification and/or risk assessment, and which has been determined to provide equivalent or improved protection of human or animal health or the environment, as applicable, compared to the accepted test, for all possible testing situations and chemicals (16).

**Reproducibility:** The agreement among results obtained from repeated testing of the same test chemical using the same test protocol (See "Reliability") (16).

**Reversible effects on the eye:** See “Eye irritation”.

**RhCE:** Reconstructed human Cornea-like Epithelium.

**Run:** A run consists of one or more test chemicals tested concurrently with a negative control and with a positive control.

**SD:** Standard Deviation.

**Sensitivity:** The proportion of all positive/active test chemicals that are correctly classified by the test. It is a measure of accuracy for a test method that produces categorical results, and is an important consideration in assessing the relevance of a test method (16).

**Serious eye damage:** Production of tissue damage in the eye, or serious physical decay of vision, following application of a test substance to the anterior surface of the eye, which is not fully reversible within 21 days of application. Interchangeable with “Irreversible effects on the eye” and with “UN GHS Category 1” (1).

**Standard Operating Procedures (SOP):** Formal, written procedures that describe in detail how specific routine, and test-specific, laboratory operations should be performed. They are required by GLP.
**Specificity:** The proportion of all negative/inactive test chemicals that are correctly classified by the test. It is a measure of accuracy for a test method that produces categorical results and is an important consideration in assessing the relevance of a test method (16).

**Substance:** Chemical elements and their compounds in the natural state or obtained by any production process, including any additive necessary to preserve the stability of the product and any impurities deriving from the process used, but excluding any solvent which may be separated without affecting the stability of the substance or changing its composition (1).

**Test:** A single test chemical concurrently tested in a minimum of two tissue replicates as defined in the corresponding SOP.

**Tissue viability:** Parameter measuring total activity of a cell population in a reconstructed tissue as their ability to reduce the vital dye MTT, which, depending on the endpoint measured and the test design used, correlates with the total number and/or vitality of living cells.

**Top-Down approach:** Step-wise approach used for a chemical suspected of causing serious eye damage, which starts with the determination of chemicals inducing serious eye damage (positive outcome) from other chemicals (negative outcome).

**Test chemical:** The term "test chemical" is used to refer to what is being tested.

**Tiered testing strategy:** A stepwise testing strategy, which uses test methods in a sequential manner. All existing information on a test chemical is reviewed at each tier, using a weight-of-evidence process, to determine if sufficient information is available for a hazard classification decision, prior to progression to the next tier in the strategy. If the hazard potential/potency of a test chemical can be assigned based on the existing information at a given tier, no additional testing is required (16).

**ULOQ:** Upper Limit of Quantification.

**United Nations Globally Harmonized System of Classification and Labelling of Chemicals (UN GHS):** A system proposing the classification of chemicals (substances and mixtures) according to standardised types and levels of physical, health and environmental hazards, and addressing corresponding communication elements, such as pictograms, signal words, hazard statements, precautionary statements and safety data sheets, so that to convey information on their adverse effects with a view to protect people (including employers, workers, transporters, consumers and emergency responders) and the environment (1).

**UN GHS Category 1:** See “Serious eye damage”.

**UN GHS Category 2:** See “Eye irritation”.

**UN GHS No Category:** Chemicals that do not meet the requirements for classification as UN GHS Category 1 or 2 (2A or 2B). Interchangeable with “Not Classified”.

**UPLC:** Ultra-High Performance Liquid Chromatography.

**UVCB:** substances of unknown or variable composition, complex reaction products or biological materials.
Valid test method: A test method considered to have sufficient relevance and reliability for a specific purpose and which is based on scientifically sound principles. A test method is never valid in an absolute sense, but only in relation to a defined purpose (16).

Validated test method: A test method for which validation studies have been completed to determine the relevance (including accuracy) and reliability for a specific purpose. It is important to note that a validated test method may not have sufficient performance in terms of accuracy and reliability to be found acceptable for the proposed purpose (16).

VRM: Validated Reference Method.

VRM1: EpiOcular™ EIT is referred as the Validated Reference Method 1.

VRM2: SkinEthic™ HCE EIT is referred to as the Validated Reference Method 2.

Weight-of-evidence: The process of considering the strengths and weaknesses of various pieces of information in reaching and supporting a conclusion concerning the hazard potential of a test substance.
# ANNEX II

## MAIN TEST METHOD COMPONENTS OF THE RhCE TEST METHODS VALIDATED FOR EYE IRRITATION OR SEERIOUS EYE DAMAGE

<table>
<thead>
<tr>
<th>Test Method Components</th>
<th>EpiOcular™ EIT (VRM 1)</th>
<th>SkinEthic™ HCE EIT (VRM 2)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Protocols</td>
<td>Liquids (pipetteable at 37°C or lower temperatures for 15 min)</td>
<td>Solids (not pipetteable)</td>
</tr>
<tr>
<td>Model surface</td>
<td>0.6 cm²</td>
<td>0.6 cm²</td>
</tr>
<tr>
<td>Number of tissue replicates</td>
<td>At least 2</td>
<td>At least 2</td>
</tr>
<tr>
<td>Treatment doses and application</td>
<td>Pre-treatment 20 µL Ca²⁺/Mg²⁺-free DPBS for 30 ± 2 min at 37°C, 5% CO₂, 95% RH, protected from light. Test chemical exposure + 50 µL (83.3 µL/cm²)</td>
<td>Pre-treatment 20 µL Ca²⁺/Mg²⁺-free DPBS for 30±2 min at 37°C, 5% CO₂, 95% RH, protected from light. Test chemical exposure + 50 µg (83.3 mg/cm²)</td>
</tr>
<tr>
<td>Pre-check for direct MTT reduction</td>
<td>50 µL + 1 mL MTT 1 mg/mL solution for 180 min at 37°C, 5% CO₂, 95% RH → if solution turns blue/purple, freeze-killed adapted controls should be performed</td>
<td>50 mg + 1 mL MTT 1 mg/mL solution for 180 min at 37°C, 5% CO₂, 95% RH → if solution turns blue/purple, freeze-killed adapted controls should be performed</td>
</tr>
<tr>
<td>Test Method Components</td>
<td>EpiOcular™ EIT (VRM 1)</td>
<td>SkinEthic™ HCE EIT (VRM 2)</td>
</tr>
<tr>
<td>------------------------</td>
<td>------------------------</td>
<td>-----------------------------</td>
</tr>
</tbody>
</table>
| Pre-check for colour interference | 50 µL + 2 mL isopropanol for 2-3h at RT  
→ if at 570±30 nm, the OD > 0.08 after subtraction of the OD for isopropanol or water, which corresponds to approximately 5% of the mean OD of the negative control, living adapted controls should be performed | 10 µL + 90 µL H₂O mixed for 30 min at Room Temperature (RT, 18-28°C)  
→ if test chemical is coloured, living adapted controls should be performed |

| Exposure time and temperature | 30 min (± 2 min) in culture medium at 37°C, 5% CO₂, 95% RH | 30 min (± 2 min) in culture medium at 37°C, 5% CO₂, 95% RH  
4 hours (± 0.1 h) in culture medium at 37°C, 5% CO₂, 95% RH |
| Rinsing | 3 times in 100 mL of Ca²⁺/Mg²⁺-free DPBS | 20 mL Ca²⁺/Mg²⁺-free DPBS  
25 mL Ca²⁺/Mg²⁺-free DPBS |
| Post-exposure immersion | 12 min (± 2 min) at RT in culture medium | 30 min (± 2 min) at 37°C, 5% CO₂, 95% RH in culture medium  
30 min (± 2 min) at RT in culture medium |
| Post-exposure incubation | 120 min (± 15 min) in culture medium at 37°C, 5% CO₂, 95% RH | 18 h (± 0.25 h) in culture medium at 37°C, 5% CO₂, 95% RH  
none  
18 h (± 0.5 h) in culture medium at 37°C, 5% CO₂, 95% RH |
| Negative control | 50 µL H₂O Tested concurrently | 30 ± 2µL Ca²⁺/Mg²⁺-free DPBS Tested concurrently  
30 ± 2µL Ca²⁺/Mg²⁺-free DPBS Tested concurrently |
| Positive control | 50 µL Methyl acetate Tested concurrently | 30 ± 2µL Methyl acetate Tested concurrently  
30 ± 2µL Methyl acetate Tested concurrently |
| MTT solution | 300 µL 1 mg/mL | 300 µL 1 mg/mL  
300 µL 1 mg/mL  
300 µL 1 mg/mL |
<table>
<thead>
<tr>
<th>Test Method Components</th>
<th>EpiOcular™ EIT (VRM 1)</th>
<th>SkinEthic™ HCE EIT (VRM 2)</th>
</tr>
</thead>
<tbody>
<tr>
<td>MTT incubation time and temperature</td>
<td>180 min (± 15 min) at 37°C, 5% CO₂, 95% RH</td>
<td>180 min (± 15 min) at 37°C, 5% CO₂, 95% RH</td>
</tr>
<tr>
<td>Extraction solvent</td>
<td>2 mL isopropanol (extraction from top and bottom of insert by piercing the tissue)</td>
<td>1.5 mL isopropanol (extraction from top and bottom of insert)</td>
</tr>
<tr>
<td>Extraction time and temperature</td>
<td>2-3 h with shaking (~120 rpm) at RT or overnight at 4-10°C</td>
<td>4 h with shaking (~120 rpm) at RT or at least overnight without shaking at 4-10°C</td>
</tr>
<tr>
<td>OD reading</td>
<td>570 nm (550 - 590 nm) without reference filter</td>
<td>570 nm (540 - 600 nm) without reference filter</td>
</tr>
<tr>
<td>Tissue Quality Control</td>
<td>Treatment with 100 µL of 0.3% (v/v) Triton X-100 12.2 min ≤ ET₅₀ ≤ 37.5 min</td>
<td>Treatment with 100 µL of 0.3% (v/v) Triton X-100 12.2 min ≤ ET₅₀ ≤ 37.5 min</td>
</tr>
<tr>
<td></td>
<td>30 min treatment with SDS 1.0 mg/mL ≤ IC₅₀ ≤ 3.5 mg/mL</td>
<td>30 min treatment with SDS 1.0 mg/mL ≤ IC₅₀ ≤ 3.5 mg/mL</td>
</tr>
<tr>
<td>Acceptability Criteria</td>
<td>1. Mean OD of the tissue replicates treated with the negative control should be ≥ 0.8 and &lt; 2.5 2. Mean viability of the tissue replicates exposed for 30 min with the positive control, expressed as % of the negative control, should be ≤ 50% 3. The two tissue replicates should not exceed 20%.</td>
<td>1. Mean OD of the tissue replicates treated with the negative control should be ≥ 1.0 and ≤ 2.5 2. Mean viability of the tissue replicates exposed for 6 hours with the positive control, expressed as % of the negative control, should be ≤ 50% 3. The two tissue replicates should not exceed 20%.</td>
</tr>
</tbody>
</table>
ILLUSTRATIVE FLOWCHART PROVIDING GUIDANCE ON HOW TO IDENTIFY AND HANDLE DIRECT MTT-REDUCERS AND/OR COLOUR INTERFERING CHEMICALS, BASED ON THE VRMI SOP

ANNEX III

PRE-CHECK FOR COLOUR INTERFERENCE

- Incubate 50 µL or 50 mg of test chemical in 1 mL of water for 1 hour at standard culture conditions.
- Incubate 50 µL or 50 mg of test chemical in 2 mL of isopropanol for 2-3 hours at room temperature.

Is the OD at 570±30 nm higher than 0.08?

- No
- Yes

Is the colour of the chemical too strong to allow a conclusive pre-check for direct MTT reduction?

- No
- Yes

Consider one of the following options:

- Use CO or HPLC/UPLC-spectrophotometry
- Use CO or HPLC/UPLC-spectrophotometry
- Use HPLC/UPLC-spectrophotometry
- Use CO

Does the mature turn bluish-purple?

- No
- Yes

Perform living tissue control concurrently with every test performed, following full testing procedure but incubating with medium instead of MTT (+ %NSC<sub>MTT</sub>.) AND

Perform killed tissue control following full testing procedure but incubating with medium instead of MTT (+ %NSC<sub>MTT</sub>) (one is sufficient to correct multiple tests)

- No controls are required
- Final % viability = % uncorrected test viability - %NSC<sub>MTT</sub>

Final % viability = % uncorrected test viability - %NSC<sub>bluish</sub> + %NSC<sub>MTT</sub> + %NSC<sub>control</sub>

Final % viability = % uncorrected test viability - %NSC<sub>bluish</sub>

No controls are required
ANNEX IV
ILLUSTRATIVE FLOWCHART PROVIDING GUIDANCE ON HOW TO IDENTIFY AND HANDLE DIRECT MTT-REDUCERS AND/OR COLOUR INTERFERING CHEMICALS, BASED ON THE VRM2 SOP

PRE-CHECK FOR COLOUR INTERFERENCE
Incubate 10 µL or 10 mg of test chemical in 90 µL of water for 30 minutes at room temperature

Does the mixture turn coloured?

Yes

PRE-CHECK FOR DIRECT MTT REDUCTION
Incubate 30 µL or 30 mg of test chemical in 300 µL of 1 mg/mL MTT solution for 3 hours at standard culture conditions

Does the mixture turn blue/purple?

No

Use OD or HPLC/UPLC-spectrophotometry
Perform living-tissue control concurrently with every test performed, following full testing procedure but incubating with medium instead of MTT (= %NSC<sub>living</sub>)

AND

Perform killed-tissue control following full testing procedure but incubating with medium instead of MTT (= %NSC<sub>killed</sub>) (one is sufficient to correct multiple tests)

No controls are required

Final %viability = %uncorrected test viability - %NSMTT

Yes

Consider one of the two following options

Incubate 30 µL or 30 mg of test chemical in 300 µL of 1 mg/mL MTT solution for 3 hours at standard culture conditions

Is the colour of the chemical too strong to allow a conclusive pre-check for direct MTT reduction?

No

Use OD or HPLC/UPLC-spectrophotometry
Perform living-tissue control concurrently with every test performed, following full testing procedure but incubating with medium instead of MTT (= %NSC<sub>living</sub>)

AND

Perform killed-tissue control following full testing procedure but incubating with medium instead of MTT (= %NSC<sub>killed</sub>) (one is sufficient to correct multiple tests)

No controls are required

Final %viability = %uncorrected test viability - %NSMTT + %NSC<sub>killed</sub>

Yes

Does the mixture turn blue/purple?

No

Perform living-tissue control concurrently with every test performed, following full testing procedure but incubating with medium instead of MTT (= %NSC<sub>living</sub>)

AND

Perform killed-tissue control following full testing procedure but incubating with medium instead of MTT (= %NSC<sub>killed</sub>) (one is sufficient to correct multiple tests)

No controls are required

Final %viability = %uncorrected test viability - %NSMTT

No

Use OD

Perform living-tissue control concurrently with every test performed, following full testing procedure but incubating with medium instead of MTT (= %NSC<sub>living</sub>)

AND

Perform killed-tissue control following full testing procedure but incubating with medium instead of MTT (= %NSC<sub>killed</sub>) (one is sufficient to correct multiple tests)

No controls are required

Final %viability = %uncorrected test viability - %NSMTT

© OECD, (2016)
ANNEX V

KEY PARAMETERS AND ACCEPTANCE CRITERIA FOR QUALIFICATION OF AN HPLC/UPLC-SPECTROPHOTOMETRY SYSTEM FOR MEASUREMENT OF MTT FORMAZAN EXTRACTED FROM RHCE TISSUE CONSTRUCTS

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Protocol Derived from FDA Guidance (36)(38)</th>
<th>Acceptance Criteria</th>
</tr>
</thead>
<tbody>
<tr>
<td>Selectivity</td>
<td>Analysis of isopropanol, living blank (isopropanol extract from living RHCE tissue constructs without any treatment), dead blank (isopropanol extract from killed RHCE tissue constructs without any treatment), and of a dye (e.g., methylene blue)</td>
<td>Area_{interference} ≤ 20% of Area_{LLOQ} (^1)</td>
</tr>
<tr>
<td>Precision</td>
<td>Quality Controls (i.e., MTT formazan at 1.6 µg/mL, 16 µg/mL and 160 µg/mL in isopropanol (n=5)</td>
<td>CV ≤ 15% or ≤ 20% for the LLOQ</td>
</tr>
<tr>
<td>Accuracy</td>
<td>Quality Controls in isopropanol (n=5)</td>
<td>%Dev ≤ 15% or ≤ 20% for LLOQ</td>
</tr>
<tr>
<td>Matrix Effect</td>
<td>Quality Controls in living blank (n=5)</td>
<td>85% ≤ %Matrix Effect ≤ 115%</td>
</tr>
<tr>
<td>Carryover</td>
<td>Analysis of isopropanol after an ULOQ(^2) standard</td>
<td>Area_{interference} ≤ 20% of Area_{LLOQ}</td>
</tr>
<tr>
<td>Reproducibility (intra-day)</td>
<td>3 independent calibration curves (based on 6 consecutive 1/3 dilutions of MTT formazan in isopropanol starting at ULOQ, i.e., 200 µg/mL; Quality Controls in isopropanol (n=5)</td>
<td>Calibration Curves: %Dev ≤ 15% or ≤ 20% for LLOQ</td>
</tr>
<tr>
<td>Reproducibility (inter-day)</td>
<td>Day 1: 1 calibration curve and Quality Controls in isopropanol (n=5)</td>
<td>Quality Controls: %Dev ≤ 15% and CV ≤ 15%</td>
</tr>
<tr>
<td>Day 2: 1 calibration curve and Quality Controls in isopropanol (n=5)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Day 3: 1 calibration curve and Quality Controls in isopropanol (n=5)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Short Term Stability of MTT Formazan in RhCE Tissue Extract</td>
<td>Quality Controls in living blank (n=3) analysed the day of the preparation and after 24 hours of storage at room temperature</td>
<td>%Dev ≤ 15%</td>
</tr>
<tr>
<td>Long Term Stability of MTT Formazan in RhCE Tissue Extract, if required</td>
<td>Quality Controls in living blank (n=3) analysed the day of the preparation and after several days of storage at -20°C</td>
<td>%Dev ≤ 15%</td>
</tr>
</tbody>
</table>

\(^1\) LLOQ: Lower Limit of Quantification, defined to cover 1-2% tissue viability, i.e., 0.8 µg/mL.

\(^2\) ULOQ: Upper Limit of Quantification, defined to be at least two times higher than the highest expected MTT formazan concentration in isopropanol extracts from negative controls (~70 µg/mL in the VRM), i.e., 200 µg/mL.